Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study

• Published in: Current medical research and opinion Vol. 38; no. 5; pp. 731 - 742
• Main Authors: Pozo-Rosich, Patricia, Detke, Holland C., Wang, Shufang, Doležil, David, Li, Lily Q., Aurora, Sheena K., Reuter, Uwe
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 04.05.2022
• Subjects: Adolescent; Adult; Aged; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - adverse effects; CGRP; chronic migraine; Double-Blind Method; Galcanezumab; Humans; long-term; Middle Aged; Migraine Disorders - drug therapy; Migraine Disorders - prevention & control; open-label extension; preventive treatment; Treatment Outcome; Young Adult; Galcanezumab; chronic migraine; open-label extension; preventive treatment; CGRP; long-term

Galcanezumab, a monoclonal antibody to calcitonin gene-related peptide, was found to be safe and efficacious for the preventive treatment of chronic migraine based on the randomized, placebo-controlled double-blind period of the REGAIN study. Long-term safety and efficacy were assessed in an open-la...